Introduction {#Sec1}
============

This guideline development process was initiated within the frame of the "European network and registry for homocystinurias and methylation defects" (E-HOD) project, which was started in February 2013. The main aims of the project are the formation of a sustainable international collaboration of experts and clinically active centres, development of guidelines and establishment of a disease registry for homocystinurias and methylation defects. Given the often significant delays in diagnosis and the absence of standardised treatment protocols, the evaluation of the published knowledge and delineation of guidelines for diagnosis and treatment of these rare diseases are urgently needed. Most of the existing studies and reports are non-systematic, observational studies, case series or case reports, which are generally considered to be low quality evidence. However, following collation of the available evidence some very consistent patterns evolved. Confirmation and validation of our observations by insights gained from other fields of research (e.g. vitamin B12 deficiency in the elderly) additionally informed our interpretation of the evidence.

Homocysteine (Hcy) is an amino acid formed from methionine (Met). Under normal circumstances Hcy is converted into cysteine (transulfuration pathway) or remethylated (remethylation pathway) forming Met.

All genetic remethylation defects share deficient activity of methionine synthase due to various reasons: decreased function of the methionine synthase enzyme protein itself or of the associated enzyme methionine synthase reductase; deficient production of the cofactor, methyl-cobalamin; or disturbed supply of the substrate methyl-tetrahydrofolate (MTHF). Some genetic disorders of intracellular cobalamin (cbl) transport and processing (cblC, cblD-MMA/Hcy, cblF and cblJ) cause deficient synthesis not only of methylcobalamin but also of adenosylcobalamin, the cofactor for methylmalonyl-CoA mutase. Those combined remethylation disorders are associated with increased Hcy and methylmalonic acid (MMA). 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency leads to impaired provision of 5-MTHF resulting in decreased function of methionine synthase (Fowler [@CR59]) (Fig. [1](#Fig1){ref-type="fig"})Fig. 1Remethylation disorders: metabolic pathways. *MTHFR* methylenetetrahydrofolate reductase, *THF* tetrahydrofolate, *Gly* glycine, *Ser* serine, *DHF* dihydrohydrofolate, *Met* methionine, *Hcy* homocysteine, *AdoMet* adenosylmethionine, *AdoHcy* adenosylhomocysteine, *MS* methionine synthase, *MSR* methionine synthase reductase, *BHMT* betaine homocysteine methyltransferase, *CBS* cystathionine-beta-synthase, *DMG* dimethylglycine, *MeCbl* methylcobalamin, *AdoCbl* adenosyl-Cbl.

Our understanding of the pathophysiology of the remethylation disorders and MTHFR deficiency is incomplete. At present, there are five main hypotheses: (A) direct toxicity of metabolites, (B) missing products, (C) impaired methylation capacity, (D) oxidative stress, (E) impaired non-enzymatic protein functions.(A)Hyperhomocysteinaemias are predominantly associated with neurocognitive and vascular pathology. Homocysteine and its metabolic product, homocysteic acid, have been implicated in provocation of seizures in rats (Kubová et al [@CR110]; Mares et al [@CR128]). Besides its impact on renal function, accumulation of MMA along with dicarboxylic acids like 2-methylcitrate and propionyl-CoA have been found to induce synergistic mitochondrial dysfunction (Morath et al [@CR142]; Zsengellér et al [@CR236]).(B)Impaired methionine synthase activity with accumulation of intracellular 5-MTHF (folate trap) and subsequent disruption of nucleotide synthesis compromise rapidly proliferating tissues such as bone marrow or epithelia. In MTHFR deficiency, this trapping of folates is not found but 5-methylTHF synthesis is impaired, resulting in low levels of methyl-tetrahydrofolate (CH3-THF) in the central nervous system of unknown significance (Schiff and Blom [@CR180]).(C)Remethylation of homocysteine (Hcy) is an important mechanism that maintains the methylation capacity of the organism and removes excess Hcy. Methylation reactions such as DNA methylation, creatine and myelin synthesis utilise S-adenosylmethionine (SAM), a metabolite formed from Met as the methyl group donor. Accordingly, any disorder or disruption of the Met-Hcy-SAM pathway affects methylation capacity by impairing multiple metabolic systems and processes (King et al [@CR106]; Surtees et al [@CR200]).(D)Enhanced oxidative stress due to a disturbance of glutathione metabolism has been shown in patients with the cblC defect and may contribute to the underlying pathophysiology (Pastore et al [@CR156]).(E)Recent data suggest that not only the accumulation of metabolites but also the perturbed non-enzymatic functions, e.g. of the MMACHC protein may add to the pathophysiology behind the disease (Moreno-Garcia et al [@CR146]; Brooks et al [@CR28]).

Methods {#Sec2}
=======

Panelists involved in the guideline process were invited by the EHOD project leaders according to their expertise regarding the diseases in terms of biochemistry; genetics; clinical, psychosocial and laboratory diagnosis and patient management and/or research activities.

The PubMed and Cochrane databases were searched using the following terms: remethylation defects OR severe mthfr OR severe methylenetetrahydrofolate reductase OR cblc OR cbld OR cblf OR cblj OR cble OR cblg OR methylmalonic aciduria homocystinuria OR methylmalonic aciduria homocystinuria OR methylmalonic acidemia homocysteinemia OR methylmalonic aciduria homocysteinemia OR "Cobalamin C OR Cobalamin D OR Cobalamin E OR Cobalamin F OR Cobalamin G OR Cobalamin J" (last update February 2016: 834 publications).

The resulting list of publications was disposed of all articles predominantly or only addressing other diseases (e.g. classical homocystinuria) or MTHFR polymorphisms (e.g. C677T) or without information relevant to the outcomes of interest (e.g. mutation reports only) by screening of abstracts. In total, 174 publications were included in the qualitative data analysis. The clinical characterisation of the diseases (Table [1](#Tab1){ref-type="table"}) was based on 117 publications.Table 1Signs and symptoms reported in 396 individuals. ++++ Very frequently (\>50 % of cases); +++ frequently (25--50 % of cases); ++ infrequently (10--25 % of cases); + occasionally seen (\<10 % of cases). (+) Single case reports, probably disease-related conditionscblCcblD-MMA/HCcblFcblD-HCcblEcblGMTHFR deficiencyNumber of reported cases169161352025148Eating disorders/failure to gain weight Small for gestational age+++(+) Feeding difficulties, failure to thrive+++++++++++++++++++Nervous system Decreased consciousness +/− apnoea++(+)+++++++++ Seizures+++++++++(++)+++++++++ Ataxia+(++)(+)++++ Movement disorder and/or abnormal muscle tone+++++++++++++++++++++++ Peripheral neuropathy/subacute degeneration of spinal cord++(+)(++)++++++ Hydrocephalus++++++++ Visual impairment (retinopathy, optic atrophy)+++++++++++++ Developmental disorder/ cognitive impairment++++++++++++++++++++++++++ Behavioural/mental disorders++++++++(+)++ Microcephaly+++++++++++Blood and bone marrow Megaloblastic anaemia+++++++++++++++++++ Pancytopenia/neutropenia++++++++ Recurrent severe infections(+)++Kidneys Haemolytic uraemic syndrome++++++(+) Glomerulopathy+(+) Tubulointerstitial nephropathy+Cardiopulmonary Cardiac malformation++++ Cardiomyopathy++ Interstitial pneumonia+ Pulmonary hypertension+Vascular Stroke(+)(+)+ Venous thrombosis/ embolism+(+)+Malformations Facial dysmorphism+(+) Skeletal deformity(+)+Gastrointestinal Cheilitis/gastritis+++ Liver steatosis+++ Skin Dermatitis/rash/hyperpigmentation++++Other Hydrops fetalis+ Metabolic acidosis and/or hyperammonaemia+ Temperature instability/hypothermia+(+)Legend: The frequencies depicted in Table [1](#Tab1){ref-type="table"} are derived from collated case reports and may not be fully representative. However, they do not significantly deviate from published case series (Ogier de Baulny et al [@CR153]; Carrillo-Carrasco et al [@CR47]; Fischer et al [@CR58]; Huemer et al [@CR97]). The true prevalence of organ manifestations also depends on the extent of technical investigations, especially in relation to milder forms of microangiopathy and retinopathy that may escape clinical detection. Due to the very small number of reported cblJ cases, these have not been includedReferences: Fischer et al [@CR58]; Al Essa et al [@CR1]; Al Tawari et al [@CR2]; Alfadhel et al [@CR3]; Andersson et al [@CR5]; Andersson and Shapira [@CR4]; Arai and Osaka [@CR6]; Arn et al [@CR8]; Atkinson et al [@CR9]; Augoustides-Savvopoulou et al [@CR10]; Backe et al [@CR11]; Baumgartner et al [@CR13]; Baumgartner et al [@CR14]; Beauchamp et al [@CR15]; Bellini et al [@CR16]; Ben-Shachar et al [@CR18]; Biancheri et al [@CR20]; Biancheri et al [@CR19]; Biotti et al [@CR21]; Birnbaum et al [@CR22]; Bishop et al [@CR23]; Brandstetter et al [@CR27]; Broomfield et al [@CR29]; Brunel-Guitton et al [@CR30]; Brunelli et al [@CR31]; Cappuccio et al [@CR33]; Carmel et al [@CR34]; Carmel et al [@CR35]; Carrillo-Carrasco et al [@CR39]; Carrillo-Carrasco et al [@CR47] [@CR37]; Cerone et al [@CR40]; Chang et al [@CR41]; Clayton et al [@CR42]; Coelho et al [@CR43]; Cogan et al [@CR45]; D'Aco et al [@CR48]; D'Alessandro et al [@CR49]; De Bie et al [@CR50]; Dionisi-Vici et al [@CR53]; Ellaway et al [@CR54]; Engelbrecht et al [@CR55]; Enns et al [@CR56]; Fuchs et al [@CR64]; Geraghty et al [@CR67]; Gerth et al [@CR68]; Goodman et al [@CR71]; Goyette et al [@CR74]; Goyette et al [@CR73]; Goyette et al [@CR72]; Grant et al [@CR76]; Grünert et al [@CR78]; Guigonis et al [@CR79]; Gulati et al [@CR80]; Haan et al [@CR86]; Harding et al [@CR88]; Harpey et al [@CR89]; Haworth et al [@CR90]; Holme and Ronge [@CR91]; Howard et al [@CR92]; Huemer et al [@CR93], [@CR94], [@CR95], [@CR96]; Hyland et al [@CR98]; Kanwar et al [@CR102]; Kind et al [@CR105]; Lesesve and Latger-Cannard [@CR117]; Levy et al [@CR118]; Longo et al [@CR122]; Lossos et al [@CR123]; Mah et al [@CR125]; Martinelli et al [@CR129]; Matos et al [@CR130]; Menni et al [@CR134]; Michot et al [@CR137]; Mitchell et al [@CR140]; Morel et al [@CR144]; Mudd and Freeman [@CR148]; Nishimura et al [@CR151]; Ogier de Baulny et al [@CR153]; Pasquier et al [@CR155]; Patton et al [@CR157]; Paul et al [@CR158]; Powers et al [@CR160]; Prasad et al [@CR161]; Profitlich et al [@CR162], [@CR163]; Regland et al [@CR166]; Ribes et al [@CR167]; Ricci et al [@CR168]; Ronge and Kiellman [@CR170]; Rosenblatt et al [@CR171]; Rosenblatt et al [@CR172]; Rossi et al [@CR174]; Rutsch et al [@CR178]; Schiff et al [@CR181]; Schimel and Mets [@CR182]; Selzer et al [@CR185]; Shih et al [@CR187]; Shinnar and Singer [@CR188]; Sibani et al [@CR189]; Smith and Bodamer [@CR190]; Steen et al [@CR195]; Stucki et al [@CR197]; Suormala et al [@CR199]; Tanpaiboon et al [@CR202]; Tomaske et al [@CR204]; Tonetti et al [@CR206]; Traboulsi et al [@CR208]; Ucar et al [@CR214]; Urbón Artero et al [@CR215]; Urreizti et al [@CR216]; Visy et al [@CR219]; Waggoner et al [@CR220]; Wang et al [@CR224]; Watkins and Rosenblatt [@CR225]; Wu et al [@CR231]

The following main questions and outcomes of interest in males and females with any type of onset (early or late) of one of the diseases of interest were addressed (outcomes in parentheses).Which clinical signs are characteristic and allow timely diagnosis (Outcome: timely clinical diagnosis; this outcome is considered important)Which biochemical parameters allow timely and valid diagnosis? (Outcome: valid, timely laboratory diagnosis; this outcome is considered important)How can we prevent death and avoid/treat severe organ damage (Outcome: survival, severe organ complications; this outcome is considered critical)How can we prevent or treat eye disease and neurocognitive impairment? (Outcome: visual and neurocognitive function; this outcome is considered critical)

In a first step, all reports made available to the panelists were graded according to the Scottish Intercollegiate Guidelines Network (SIGN) criteria by the authors who had assigned themselves according to their expertise to five major working groups focusing on the topics "clinical signs and symptoms"; "differential diagnosis"; "laboratory/biochemical parameters"; "disease course and outcome"; "treatment". Due to the rarity of the diseases, studies and reports of all types of designs (from case reports and case series to metaanalyses) were included; randomised controlled trials were not available.

The working groups prepared drafts on their topics, which were carefully evaluated in moderated discussion groups. Elaboration and grading of recommendations was accomplished by moderated, consensus-oriented discussions according to the "Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group" approach (<http://www.gradeworkinggroup.org/>; Guyatt et al [@CR82], [@CR83], [@CR84], [@CR85]); a patient representative was present at these meetings. Finally, for each outcome the quality of the evidence was rated in one of three categories (low, moderate, high) as defined by the GRADE working group. The strength of a recommendation (strong recommendation, recommendation and suggestion; for more information see [Supplementary material](#Sec52){ref-type="sec"}) was summarised from written assessments from the panelist using the following set of questions:Are you confident that the benefits outweigh the harms/burden or vice versa?Is there high, moderate or low quality evidence? Please consider:Risk of biasStudy designDirectness and consistency of resultsMagnitude of effectDose--response gradientPublication biasAre you confident that the recommendation meets typical values and preferences of the target population (e.g. patients, parents)?Are the resources worth the expected net benefit following the recommendation?Overall strength of recommendation: weak or strong?

Data derived from case reports, case series or any other type of observational studies were by principle rated as low quality evidence. However, evidence for some outcomes was considered moderate on the basis of high consistency of results. High quality of evidence was only available for betaine treatment in MTHFR deficiency. This evidence was based on a metaanalysis, which revealed direct and consistent results as well as a relationship between time of onset of treatment and outcome.

Which clinical signs are characteristic for remethylation defects and allow for timely diagnosis? {#Sec3}
=================================================================================================

General clinical patterns of remethylation disorders {#Sec4}
----------------------------------------------------

The published clinical presentations of patients suffering from remethylation disorders (summarised in Table [1](#Tab1){ref-type="table"}) reveal no specific, distinct signs and symptoms but rather highlight that these conditions affect multiple systems and thus often present in a rather multifaceted manner. Nevertheless, a few patterns of clinical presentations can be identified.

Most prominently, the central and peripheral nervous system and the bone marrow are affected. Developmental and neurocognitive impairment, feeding problems, neurological symptoms including seizures, movement disorders, abnormal muscle tone, visual impairment, neuropathy and haematological abnormalities are present in the majority of patients. In many patients, renal manifestations, e.g. atypical haemolytic uraemic syndrome (HUS) or glomerulopathy, mostly related to microangiopathy, have been identified.

Clinical presentations may vary considerably. Severe acute encephalopathy, macrocytic anaemia, atypical HUS, cardiopulmonary signs, subacute combined degeneration of the cord or psychiatric symptoms, each isolated or in combination with other symptoms may be present. Therefore, in particular, a combination of neurological and haematological symptoms, often in the presence of failure to thrive or feeding difficulties should raise suspicion of a remethylation disorder (see references to Table [1](#Tab1){ref-type="table"}).

Age specific patterns of remethylation disorders {#Sec5}
------------------------------------------------

Findings from published case reports indicate that the patterns of clinical manifestation of remethylation disorders vary with age (**Table** [2](#Tab2){ref-type="table"}).Table 2Age-related clinical presentations of remethylation disordersNeonates (0--28 days) Encephalopathy  Lethargy, apnoea  Feeding difficulties  Muscular hypotonia  Seizures Nystagmus Anaemia/thrombocytopenia or pancytopenia, megaloblastosis Haemolytic uremic syndrome Cardiomyopathy Hydrocephalus Pulmonary hypertensionInfants (1--12 months) Growth failure/poor weight gain Acute progressive encephalopathy/apnoea Chronic encephalopathy  Muscular hypotonia  Developmental disability/regression  Seizures  Recurrent acute behavioural changes/lethargy Visual inattention/Nystagmus Anaemia/thrombocytopenia or pancytopenia, megaloblastosis Haemolytic uremic syndrome Pulmonary hypertensionChildren (1--12 years) Chronic Encephalopathy  Muscular hypotonia or spasticity  Developmental disability/regression or dementia  Seizures  Neuropsychiatric disturbance/personality changes  Intermittent acute behavioural changes/lethargy Acute progressive encephalopathy/apnoea Subacute degeneration of the cord  Paraesthesia  Incontinence  Ataxia/spasticity  Progressive limb weakness (legs\>arms) Haemolytic uremic syndrome Thromboembolic events  Recurrent venous thrombosis  Pulmonary thromboembolism  Cerebrovascular events Pulmonary hypertensionAdolescents and adults (\>12 years) Chronic encephalopathy  Developmental disability/regression or dementia  Neuropsychiatric disturbance  Personality changes  Intermittent acute behavioural changes/lethargy Acute progressive encephalopathy Subacute degeneration of the spinal cord  Paraesthesia  Incontinence  Ataxia/spasticity Progressive limb weakness (legs\>arms) Thromboembolic events  Recurrent venous thrombosis  Pulmonary thromboembolism  Cerebrovascular events Pulmonary hypertension

Clinical patterns specific for combined remethylation disorders (cblC, cblD-MMA/HC, cblF, cblJ) {#Sec6}
-----------------------------------------------------------------------------------------------

Severe intrauterine growth retardation is rare, whereas postnatal growth failure and feeding difficulties are very frequent. Three quarters of children with combined disorders manifest during the neonatal period or in early infancy. Neonates typically show lethargy, seizures and muscular hypotonia, often in combination with megaloblastic anaemia or neutropenia/pancytopenia. Up to 50 % of infants exhibit signs of visual impairment such as nystagmus on the background of retinopathy or optic atrophy (Bonafede et al [@CR25]; Weisfeld-Adams et al [@CR228]; Brooks et al [@CR28]). Microangiopathic renal or pulmonary disease mostly manifests early but may also be present in older children or adults (Grangé et al [@CR75]; Kömhoff et al [@CR108]; Sharma et al [@CR186]).

Older infants and young children often show signs of acute encephalopathy; visual and cognitive impairment are prevalent. Older children, adolescents and adults may present with acute or chronic behavioural or psychiatric abnormalities, cognitive impairment, signs of peripheral neuropathy and ataxia that reflect subacute degeneration of the spinal cord or rarely venous thromboembolism (Rahmandar et al [@CR164]; Huemer et al [@CR94]; Grangé et al [@CR75]). Other than optic pallor, ocular manifestations are rare in late-onset cblC (Gizicki et al [@CR69]; Weisfeld-Adams et al [@CR228]).

Clinical patterns specific for isolated remethylation disorders (cblD-HC, cblE, cblG) {#Sec7}
-------------------------------------------------------------------------------------

The less prevalent isolated disorders of methionine synthase generally present similar to combined disorders. The typical clinical patterns of the cblE and the cblG defect are indistinguishable. Affected individuals usually manifest in infancy, mostly with haematological abnormalities, muscular hypotonia and neurocognitive impairment. One third of all patients present with impaired consciousness, seizures, and one quarter with signs of visual impairment. Older children and adults can manifest with signs reflecting spinal cord involvement (subacute degeneration of the spinal cord) or psychiatric symptoms (Huemer et al [@CR95]). Single cases with isolated macrocytic anaemia without neurocognitive impairment have been reported (Vilaseca et al [@CR218]; Ruiz-Mercado et al [@CR176]).

Clinical patterns specific for MTHFR deficiency {#Sec8}
-----------------------------------------------

MTHFR deficiency mainly presents in early childhood but can potentially present at any age with a high prevalence of cognitive impairment. Neonates and young infants often manifest with feeding difficulties, decreased consciousness, hydrocephalus and muscular hypotonia. Apnoea is a frequent complication (Broomfield et al [@CR29]; Diekman et al [@CR52]; Huemer et al [@CR97]; Schiff et al [@CR181]; Strauss et al [@CR196]).

Older infants and children frequently manifest with seizures and cognitive impairment, often displaying acquired microcephaly. With increasing age, peripheral neuropathy, gait abnormalities and spasticity may become evident and some older patients manifest with additional or even isolated behavioural or psychiatric disorders (Birnbaum et al [@CR22]; Michot et al [@CR137]).

Individuals with MTHFR deficiency do not usually present with haematological abnormalities. There are just a few reports of older children and adults with megaloblastic anaemia in association with long-standing neurological manifestations (Broomfield et al [@CR29]; Schiff et al [@CR181]).

**Outcome: timely clinical diagnosis** We strongly recommend consideration of an acquired or genetic disorder of remethylation in the case of neurological and/or visual and/or haematological symptoms. (Quality of the evidence: moderate)We strongly recommend considering an acquired or genetic disorder of remethylation in the case of unexplained thrombosis and/or spinal cord degeneration and/or atypical HUS. (Quality of the evidence: moderate)

Clinical differential diagnosis {#Sec9}
-------------------------------

All clinical presentations of genetic disorders of remethylation can be mimicked by common conditions, which reduce the availability of folate or cobalamin such as nutritional deficiency, acquired malabsorption or drug-associated effects (Table [3](#Tab3){ref-type="table"}). Maternal vitamin B12 deficiency due to a strict vegan diet or to undiagnosed pernicious anaemia needs to be excluded in neonates and young infants presenting with signs of a remethylation disorder or identified by newborn screening (NBS) and subnormal vitamin B12 concentrations (Scolamiero et al [@CR183]).Table 3Conditions that mimic intracellular disorders of remethylationAffecting cobalamin availability Nutritional inadequacy (maternal vitamin B12 deficiency/vegan diet) Intestinal malabsorption (e.g. genetic disorders such as Imerslund-Graesbeck syndrome gastric intrinsic factor deficiency; autoimmune or parasitic disease; short gut syndrome) Disturbed binding and cellular uptake (e.g. TC deficiency) Disturbance of intracellular metabolism (nitrous oxide)Affecting folate availability Nutritional inadequacy (maternal deficiency/dietary inadequacy) Intestinal malabsorption (acquired/genetic) Disturbed binding and cellular uptake of folate (autoimmune/genetic) Disturbance of intracellular metabolism (antifolate drugs, MTHFD1 deficiency)Other diseases with a combination of haematological and neurological symptoms Severe iron deficiency Infectious diseases (e.g. CMV/EBV/HHV6/HPVB19/HIV1) Leukaemia/myeloproliferative disorders Myelodysplastic syndromes Disorders affecting the mitochondrial respiratory chain (e.g. Pearson syndrome) UMP synthase deficiency (orotic aciduria) Thiamine transporter (SLC19A2) defect Branched chain organic acidaemia such as methylmalonic or propionic acidaemia Lysinuric protein intolerance

A number of other rare genetic diseases can mimic defects in intracellular cobalamin metabolism and should be considered in children with clinical signs and biochemical hallmarks of a remethylation disorder but with normal serum concentrations of vitamin B12 and folates: transcobalamin (TC) deficiency is biochemically and clinically indistinguishable from combined cobalamin disorders (Trakadis et al [@CR209]). The recently discovered MTHFD1 deficiency (Watkins and Rosenblatt [@CR226]) affects folate metabolism and can cause mild hyperhomocysteinaemia. The five patients described so far displayed severe megaloblastic anaemia and pancytopenia, immunological problems and renal microangiopathy (Burda et al [@CR32]).

The HCFC1 X-linked defect (cbl X, Yu et al [@CR234]) is sometimes associated with disturbed function of the CblC protein but its diagnosis can be challenging because not all affected boys have elevated homocysteine concentrations. Clinical hallmarks are neonatal or early infantile onset of severe developmental disorder, prominent epileptic seizures, cognitive impairment and a dystonic-choreatic movement disorder; moderately elevated MMA was observed in all 14 patients reported by Yu et al [@CR234] (Table [4](#Tab4){ref-type="table"}).Table 4Differential diagnosis of inborn errors of metabolism presenting with hyperhomocysteinaemiaMacrocytosis or macrocytic anaemiaMMAMetTotal vitamin B12FolatecblC\
cblD-MMA/HC+ or −↗↘↘ to nlnlnlcblF/cblJ+↗↘↘ to nlnlnlcblE/G+nl↘↘ to nlnlnlcblD-HC+ or −nl↘↘ to nlnlnlMTHFR--nl↘↘ to nlnlnl or ↘Vitamin B12 deficiency or malabsorption+↗↘ to nl↘↘nlFolate deficiency or malabsorption+nl↘ to nlnl↘↘HCFC1 (cblX)+ or −↗ or nl↘↘ to nlnlnlCBS deficiency--nlnl-↗nlnlTC deficiency+↗↘↘ to nlnl (↘)nlMTHFD1 deficiency\*+nl↘↘ to nlnlnl\*Hyperhomocysteinaemia present in some patients, normal (nl) tHcy levels in others

Which parameters allow valid and timely laboratory diagnosis? {#Sec10}
=============================================================

Patients with a suspected remethylation disorder require immediate and urgent biochemical investigation (Fig. [2](#Fig2){ref-type="fig"}). The diagnosis of remethylation disorders can be confirmed by investigations at the levels of metabolites, enzymatic studies and/or molecular genetic analysis.Fig. 2Diagnostic pathway and management of the patient with a suspected remethylation disorder. All biochemical results refer to pre-treatment samples. **N = normal**

Biochemical metabolites {#Sec11}
-----------------------

Plasma total homocysteine (tHcy) is the first biochemical parameter to assess when a remethylation disorder is suspected. THcy levels usually are \>50 but mostly \>100 μmol/L in untreated patients with remethylation disorders (Carrillo-Carrasco et al [@CR39]; Van Hove et al [@CR217]; D'Aco et al [@CR48]; Miousse et al [@CR138]).

Routinely, tHcy is measured by chromatographic methods or immunoassays. Chromatographic methods are more specific than immunoassays and are usually coupled with tandem mass spectrometry (MS/MS) detection allowing simultaneous determination of other compounds of interest for diagnosis and follow up of these diseases, e.g. Met, cysteine (Refsum et al [@CR165]) or possibly cystathionine (Stabler et al [@CR193]; Stabler et al [@CR194]).

There is no influence of the type of collection tube used (EDTA, heparinised, citrate, serum, gel separator tubes). However, blood samples should be centrifuged within 1 h or kept cold until centrifugation (\<6 h). After removal of blood cells, tHcy is stable for several weeks at 4 °C and for several years after freezing (Refsum et al [@CR165]).

Free homocystine in plasma or urine measured by conventional ion-exchange chromatography is not the method of choice since it may remain undetectable even in the presence of significantly elevated tHcy in plasma (Fowler and Jakobs [@CR60]; Moat et al [@CR141]).

To further discriminate remethylation disorders from other hyperhomocysteinaemias, determination of urinary (or plasma) MMA (Fowler and Jakobs [@CR60]), plasma Met, blood acylcarnitine profile, serum vitamin B12 and folate are required and should promptly be determined (see Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). In case shipment of urine or blood samples is difficult, an experienced laboratory should give advice on the investigation of the parameters from DBS. Treatment should not be delayed by waiting for confirmation of the exact defect.

**Outcome: valid, timely laboratory diagnosis** Recommendation 3Elevated plasma tHcy is the hallmark of remethylation disorders. We strongly recommend that investigations in patients with a suspected remethylation disorder should start with the measurement of total homocysteine in blood. We recommend the blood sample for tHcy to be centrifuged within an hour and kept at +4° or frozen until analysis. Immunoassays or chromatographic methods are suitable for tHcy measurement. (Quality of the evidence: moderate)Recommendation 4We strongly recommend against measuring free homocysteine instead of total homocysteine. (Quality of the evidence: moderate)Recommendation 5We strongly recommend that in the case of high total homocysteine, plasma and urine samples for determination of MMA, methionine, folate and vitamin B12 are to be obtained before treatment is started. (Quality of the evidence: moderate)

Differential diagnosis of biochemical parameters {#Sec12}
------------------------------------------------

Hyperhomocysteinaemia is the hallmark of the remethylation and transulfuration disorders. Mild to moderate hyperhomocysteinaemia is common in vitamin B12 or folate deficiencies but also in very severe vitamin B6 deficiency and in patients with renal failure or hypothyroidism. While megaloblastic anaemia with increased MCV and hypersegmented neutrophils on blood film are found in both vitamin B12 and folate deficiencies, elevated MMA is only observed in functional vitamin B12 deficiency (Whitehead [@CR229]).

In the case of normal serum vitamin B12 and folate levels, TC deficiency, primary remethylation and transulfuration disorders should be considered. Holotranscobalamin measurement, which unfortunately is performed only in a few laboratories shows low levels in TC deficiency; this disorder can be confirmed by molecular genetics investigation (Trakadis et al [@CR209]).

The plasma Met concentration differentiates between remethylation disorders and deficiency of CBS, a key enzyme of the transulfuration pathway. Methionine is low or normal in remethylation disorders while it is usually elevated or at least borderline normal in CBS deficiency (Mudd [@CR147]).

Megaloblastic anaemia with increased MCV is often observed in the neonatal forms of intracellular cobalamin defects (cblF, cblJ, cblC, cblD-MMA/HC, cblD-HC, cblE and cblG) but less frequently in the late onset forms of these disorders and not normally in MTHFR deficiency (Rosenblatt et al [@CR173]; Carrillo-Carrasco et al. [@CR38]).

The recently described HCFC1 defect (cbl X) has a different pathophysiological background and is beyond the scope of these guidelines. All 14 patients presented with moderately increased MMA and five of these patients had hyperhomocysteinaemia (Yu et al [@CR234]). In two of the five published patients with methylenetetrahydrofolate dehydrogenase 1 deficiency, tHcy concentrations were moderately elevated (Burda et al [@CR32]) (Table [4](#Tab4){ref-type="table"}).

Enzymatic studies {#Sec13}
-----------------

Direct enzyme assays are only available for MTHFR, methionine synthase and methionine synthase reductase (Suormala et al [@CR198]; Gulati et al [@CR80]; Olteanu and Banerjee [@CR154]). These direct enzyme assays can be problematic. MTHFR should be assayed in cultured skin fibroblasts preferably in the physiological direction of the reaction (Suormala et al [@CR198]). Apo-methionine synthase and holo-methionine synthase (methionine synthase plus methionine synthase reductase) activities can be measured by the same reaction but with different conditions of reduction (Yamada et al [@CR233]).

Indirect assays measuring the integrity of several enzymes in the same pathway are useful for remethylation disorders investigations. Incorporation of 1-\[^14^C\]-propionate into amino acids and then cell proteins via the propionate pathway reflects the level of intracellular synthesis of adenosylcobalamin. Incorporation of \[^14^C\]-methyltetrahydrofolate into methionine explores the methionine synthase and methionine synthase reductase activities and the capacity of the cells to produce methylcobalamin. Incorporation of \[^14^C\]-formate into methionine or serine reflects the activities of the methylene-tetrahydrofolate dehydrogenase, methylene-tetrahydrofolate reductase and the methionine synthase/methionine synthase reductase activities (Table [5](#Tab5){ref-type="table"}). These tests also allow the assessment of possible in vitro vitamin-responsiveness of the relevant disorders (Suormala et al [@CR198]; Gulati et al [@CR80]; Olteanu and Banerjee [@CR154]). Enzyme assays are needed to characterise functional consequences of new variants identified by molecular genetic investigations including next generation sequencing.Table 5Representation of the cobalamin defects associated with hyperhomocysteinaemia, the respective enzymatic/incorporations tests available and the genes involved in these diseasescblCcblD-MMA/HCcblFcblJcblD-HCcblEcblGMTHFRDirect enzyme assay (tissues)nononononoyesyesyesfib/leuc/amnfib/leuc/amnfib/leuc/amnIndirect enzyme assays Propionate incorporation↘↘↘↘nlnlnlnl MTHF incorporation↘↘↘↘↘↘↘nl Formate incorporation into serine↘↘↘↘↘↘↘nl or ↗ Formate incorporation into methionine↘↘↘↘↘↘↘↘ AdoCbl biosynthesis↘↘↘↘nlnlnlnl MeCbl biosynthesis↘↘↘↘↘↘↘↘Gene***MMACHC*** ^*1*^*MMADHC* ^*2*^*LMBRD1* ^*3*^*ABCD4* ^*4*^*MMADHC* ^*2*^*MTRR* ^*5*^*MTR* ^*6*^*MTHFR* ^*7*^Chromosome location1p34.12q23.26q1314q24.32q23.25p15.311q431p36.22Mode of inheritanceARARARARARARARAROMIM609831611935612625603214611935602568156570607093*fib* fibroblasts, *leuc* leukocytes, *amn* amniocytes, *AR* autosomal recessive, *nl* normal^1^Lerner-Ellis et al [@CR115]; ^2^Coelho et al [@CR43]; ^3^Rutsch et al [@CR178]; ^4^Coelho et al [@CR44]; ^5^Leclerc et al [@CR114]; ^6^Li et al [@CR119]; ^7^Goyette et al [@CR72], [@CR73]

Molecular genetic analysis {#Sec14}
--------------------------

The cblC gene (*MMACHC* OMIM 609831) is located in chromosome region 1p34.1 and has five exons (Lerner-Ellis et al [@CR115]). The three most common mutations c.271dupA, c.394C\>T and c.331C\>T have been identified in the *MMACHC* gene. The c.271dupA that represents about 30 % of the identified alleles and c.331C\>T mutations are associated with early onset disease. The c.394C\>T mutation is associated mainly with late onset disease. The c.609G\>A mutation accounts for 85 % of the identified alleles in Chinese patients, and even though it leads to a premature termination codon it remains predominantly associated with late onset disease in this population (Wang et al [@CR222]) but has been observed in some early-onset cases in other populations (Weisfeld-Adams et al [@CR227]). Other mutations have been shown to cluster according to ethnicity (Morel et al [@CR145]; Nogueira et al [@CR152]).

The precise function of MMACHC is not completely understood. Recombinant MMACHC binds cobalamin, can function in vitro as a cyanocobalamin (CNCbl) decyanase (Kim et al [@CR103]) and can dealkylate other cobalamin forms (Hannibal et al [@CR87]). MMACHC may act as an intracellular cobalamin trafficking chaperone that carries out targeted delivery of cobalamin to and from other cobalamin-related proteins (Lerner-Ellis et al [@CR116]).

In contrast to the cblC defect which presents exclusively as combined hyperhomocysteinaemia with MMA-uria, cblD patients can have three distinct biochemical phenotypes: isolated hyperhomocysteinemia (cblD-HC), isolated MMA-uria (cblD-MMA, beyond the scope of these guidelines), or combined hyperhomocysteinemia and MMA-uria (cblD-MMA/HC). *MMADHC* (OMIM 611935) is the gene responsible for cblD defect (Suormala et al [@CR199]; Coelho et al [@CR43]). Genotype--phenotype correlation analysis of the three cblD variants suggests that the N- and C-terminal regions of *MMADHC* have specific effects on functions in the mitochondrion and cytoplasm, respectively (Stucki et al [@CR197]; Miousse et al [@CR138]). cblD-HC retains mitochondrial function with a full-length protein which harbours only C-terminal missense mutations in conserved residues; cblD-MMA retains cytoplasmic function due to translation of an error-free C-terminus facilitated by downstream re-initiation; and in cblD-MMA/HC complete loss of functionality occurs with deleterious mutations that are localised downstream of Met116 (Jusufi et al [@CR101]).

To date, there have been no obvious genotype-phenotype correlations in cblF (*LMBRD1*, OMIM 612625) (Armour et al [@CR7]), cblJ (*ABCD4*, OMIM 603214) (Coelho et al [@CR44]), cblE (*MTRR*, OMIM 602568) and cblG (*MTR*, OMIM 156570) (Watkins and Rosenblatt [@CR225]; Huemer et al [@CR95]).

If clinical and biochemical parameters are characteristic for a combined remethylation disorder it may be---dependent on the population---a pragmatic approach to look first for cblC, the most frequent remethylation disorder by searching for the common mutation (c.271dupA) or MMACHC sequencing. If these analyses however prove negative, functional and/or complementation studies in fibroblasts or extended molecular genetic testing for other defects are needed.

For MTHFR deficiency (OMIM 6070993) the majority of mutations are private and neither type nor location of mutation correlates with clinical phenotype (Froese et al [@CR63]). Genetic testing for MTFHR deficiency should be interpreted with caution since there are numerous polymorphisms in this gene, which have been related to various common disorders and conditions. Polymorphisms in general including the most investigated thermolabile variant c.677C\>T in MTHFR are not responsible for severe remethylation disorders (Tsang et al [@CR212]).

**Outcome: valid, timely laboratory diagnosis** Recommendation 6We strongly recommend diagnostic confirmation by molecular genetic analysis and/or direct or indirect enzyme assays in cultured skin fibroblasts (or lymphocytes) in experienced laboratories. (Quality of the evidence: moderate)

Prenatal diagnosis {#Sec15}
------------------

Metabolites concentration (tHcy and MMA) in cell-free amniotic fluid, enzyme activity of MTHFR and methionine synthase or methionine synthase reductase in cultured amniotic cells and incorporation of propionate and methyltetrahydrofolate have been used for many years (Fowler and Jakobs [@CR60]; Merinero et al [@CR136]) and their combined use is reliable (Morel et al [@CR144]). Indirect enzyme assays in chorion biopsy should be avoided (Morel et al [@CR144]; Merinero et al [@CR136]).

However nowadays, the molecular genetic diagnosis is the most advisable method provided the causal mutations in the index case and carrier status in the parents have been identified. Molecular genetic testing can be performed from chorionic villi or amniotic fluid samples (Morel et al [@CR144]).

**Outcome: valid, timely laboratory diagnosis** Recommendation 7If prenatal diagnosis is considered in individual cases we recommend to perform molecular genetic analysis from chorionic villi or amniotic fluid samples given that mutations in the index case and carrier status in the parents have been identified (Quality of the evidence: low)

Feasibility and impact on outcome of newborn screening (NBS) for combined remethylation disorders {#Sec16}
-------------------------------------------------------------------------------------------------

NBS for the cblC defect should be considered since survival and prevention of severe complications such as HUS, hydrocephalus and haematological abnormalities in early-onset patients can be improved by early treatment (Huemer et al [@CR96]). The impact of early treatment on neurocognitive development is unclear and early treatment has little influence on eye disease (Weisfeld-Adams et al [@CR227]). In most late-onset cblC patients, dementia, renal function, myelopathy and axonal neuropathy improve on treatment and long-lasting disease existing before treatment initiation correlates with residual pathologies (Huemer et al [@CR94]). There is insufficient data on NBS for other combined remethylation disorders.

**Outcome: survival, severe organ complications; visual and neurocognitive function** Recommendation 8We strongly recommend early treatment in patients with the cblC defect as it improves survival, corrects haematological abnormalities and may prevent HUS and hydrocephalus. However, early treatment has little influence on eye disease and unclear impact on neurocognitive outcome (Quality of the evidence: moderate)

Present knowledge allows no conclusion concerning the clinical benefit of early treatment for the cblD-MMA/HC, cblF and cblJ defects.

The Region 4 Stork (R4S) data indicate that the sensitivity of C3/C2 as primary markers is superior to Met and Met/Phe (McHugh et al [@CR133]). However, specificity of C3 and/or C3/C2 for detecting these diseases is generally low (la Marca et al [@CR112]; Tortorelli et al [@CR207]). The positive predictive value substantially increased from 4 to 100 % by measurement of MMA and 11 to 36 % by measuring tHcy as second tier analytes in DBS (la Marca et al [@CR112]; Tortorelli et al [@CR207]). The sensitivity of C3 and C3/C2 for mild/late-onset forms is unknown. It is of note that neonatal metabolic disturbances due to maternal vitamin B12 deficiency may also be detected. It has recently been shown that heptadecanoyl-carnitine (C17) may have an even higher predictive value for perturbations of MMA metabolism including combined remethylation defects and may thus be a promising first tier analyte (Malvagia et al [@CR126]).

**Outcome: timely and valid laboratory diagnosis** Recommendation 9We strongly recommend to obtain plasma for determination of serum vitamin B12 before treatment is started in cases identified by NBS as part of studies to exclude maternal vitamin B12 deficiency. (Quality of the evidence: moderate)Recommendation 10We recommend use of C3 acylcarnitine and the C3/C2 ratio as primary markers to screen for early onset cblC defect. (Quality of the evidence: moderate)Recommendation 11We suggest consideration of C17 acylcarnitine as a promising primary marker to screen for early onset cblC defect. (Quality of the evidence: low)Recommendation 12We strongly recommend performing second tier testing using tHcy and MMA to improve specificity and to differentiate the defects from other disorders. (Quality of the evidence: moderate)

Feasibility and impact on outcome of NBS for isolated remethylation disorders and MTHFR deficiency {#Sec17}
--------------------------------------------------------------------------------------------------

The use of NBS for detection of the isolated remethylation disorders and the MTHFR defect appears worthy of consideration. In the cblE and cblG defect, macrocytic anaemia (Vilaseca et al [@CR218]; Kvittingen et al [@CR111]) and neurocognitive performance (Harding et al [@CR88]; Rosenblatt et al [@CR171]; Schiff et al [@CR181]; Kvittingen et al [@CR111]; Müller et al [@CR149]) often respond to treatment (Müller et al [@CR149]; Schiff et al [@CR181]). Eye disease seems not to be responsive (Huemer et al [@CR94]). Early detection by NBS and timely treatment improved short-term outcomes of two asymptomatic patients with the cblE and cblG defect and three symptomatic patients with MTHFR deficiency (Wong et al [@CR230]). Moreover, early betaine treatment has a clear positive impact on outcome in MTHFR deficiency (Diekman et al [@CR52]).

Neonatal screening for cblD-HC, cblE and cblG and for MTHFR deficiency appears to be feasible by detecting decreased methionine and methionine-to-phenylalanine ratio (Bowron et al [@CR26]) in DBS. The second-tier marker tHcy clearly differentiates patients from controls (McHugh et al [@CR133]; Tortorelli et al [@CR207]). However, sufficient data on efficacy of NBS programs for these disorders is lacking.

**Outcome: survival, severe organ damage; neurocognitive impairment** Recommendation 13We strongly recommend early identification and treatment with betaine for MTHFR deficiency. Presymptomatic betaine treatment prevents severe neurological impairment (Quality of the evidence: high)

Disease course and outcome of combined remethylation disorders {#Sec18}
--------------------------------------------------------------

Most information on complications and outcome is based on data from patients with cblC disease. There is limited data about the natural history of the other combined disorders (Table [6](#Tab6){ref-type="table"}).Table 6Main complications according to system in remethylation disordersGrowth and physical featuresPrenatal growth retardation and postnatal failure to thrive\
Dysmorphic facial featuresCNSMicrocephaly\
Hydrocephalus\
Developmental delay and/or regression; cognitive impairment ranging from executive dysfunction to severe mental retardation\
Neuropsychiatric disturbances, social withdrawal, personality changes, dementia\
Progressive encephalopathy\
Seizures\
Subacute combined degeneration of the spinal cord\
Peripheral neuropathy\
Leukoencephalopathy\
Cortical atrophyEyeNystagmus\
Maculopathy\
Progressive pigmentary retinopathy\
Optic atrophy\
Visual impairment/blindnessBlood(Macrocytic) anaemia\
Thrombocytopenia and/or neutropeniaVascularStroke\
Recurrent venous thrombosis\
Cor pulmonale or subclinical pulmonary thrombosisRenalHaemolytic-uremic syndrome\
GlomerulopathyHeartCongenital heart defects\
Left ventricular non-compaction\
Dilated cardiomyopathy\
Pulmonary hypertension

Patients with the cblC defect usually present with severe complications and historically have a poor long-term outcome (Rosenblatt et al [@CR173]; Andersson et al [@CR5]; Fischer et al [@CR58]). It is well recognised that despite treatment and improved metabolic parameters, severe complications such as developmental delay and progressive visual loss may still develop (Andersson et al [@CR5]; Enns et al [@CR56]; Patton et al [@CR157]; Fischer et al [@CR58]; Weisfeld-Adams et al [@CR228]). Even if the neurologic status stabilises or improves with therapy, the sequelae remain in a large proportion of patients (Whitehead [@CR229]; Watkins and Rosenblatt [@CR225]), especially if the initiation of treatment was delayed or insufficient (Huemer et al [@CR94]). Haematological symptoms and failure to thrive generally resolve with treatment (Martinelli et al [@CR129]; Fischer et al [@CR58]).

The late-onset phenotype has a more favourable outcome than early-onset cblC disease but is still associated with residual sequelae such as learning difficulties, neurobehavioural symptoms, neurogenic bladder and gait abnormalities (Rosenblatt et al [@CR173]) and at least one patient, in whom treatment was ceased, deteriorated and died (Thauvin-Robinet et al [@CR203]).

Mortality {#Sec19}
---------

Early detection and treatment with parenteral OHCbl appear to have decreased the mortality in newborns with cblC. A retrospective analysis of 50 patients (44 presented in the first year of life) with cblC disease reported an overall mortality rate of 30 % (Rosenblatt et al [@CR173]). Of the 13 patients that died, four were not treated, two received only cyanocobalamin (CNCbl), and three were initially treated with CNCbl and then switched to OHCbl (Rosenblatt et al [@CR173]; Carrillo-Carrasco et al [@CR47]).

Later, in the Fischer study about outcome in a series of 88 patients with the cblC defect, the mortality was 11.4 % (90 % of them with infantile onset). Treatment following various regimes of parenteral OHCbl complemented in some cases by betaine, folate/folinic acid and carnitine resulted in improvement of biochemical abnormalities, non-neurological signs and mortality (Fischer et al [@CR58]). It has been suggested that daily treatment with parenteral OH-Cbl combined with betaine would be associated with a favourable outcome (Carrillo-Carrasco et al [@CR47]).

Renal disease and microangiopathy {#Sec20}
---------------------------------

Thrombotic microangiopathy (TMA) leading to atypical HUS is the most common renal manifestation in cblC; it has also been observed in cblD-MMA/HC patients. HUS may cause hypertension, intravascular haemolysis, microscopic haematuria, proteinuria and renal function deterioration, occasionally proceeding to renal failure (Van Hove et al [@CR217]; Guigonis et al [@CR79]; Sharma et al [@CR186]; Geraghty et al [@CR67]; Morath et al [@CR143]). A case of focal segmental glomerulosclerosis and atypical glomerulopathy (Brunelli et al [@CR31]) has been reported. Histological findings of the kidneys include widening of the mesangium, swelling of endothelial cells with detachment from the basement membrane, and granular deposits in the subendothelial space (Van Hove et al [@CR217]; Russo et al [@CR177]; Brunelli et al [@CR31]; McCully [@CR131]). Isolated pulmonary hypertension has been observed (Iodice et al [@CR100]; Gündüz et al [@CR81]) in cblC patients. Early onset combined pulmonary hypertension and renal thrombotic microangiopathy with a fatal course in several untreated cases has been reported (Kömhoff et al [@CR108]), this picture is also seen in rare cases of late onset cblC patients (Grangé et al [@CR75]). Timely treatment can improve outcome significantly (Grangé et al [@CR75]; Kömhoff et al [@CR108]; Gündüz et al [@CR81]).

**Outcome: survival, severe organ complications** Recommendation 14We recommend monitoring for all aspects of renal disease including arterial blood pressure in patients with cobalamin related remethylation disorders. (Quality of the evidence: low)

Vascular problems {#Sec21}
-----------------

Thromboembolic complications are an important cause for morbidity and mortality in patients with cblC disease (Martinelli et al [@CR129]; Thauvin-Robinet et al [@CR203]). These include recurrent venous thrombosis (Thauvin-Robinet et al [@CR203]; Roze et al [@CR175]; Augoustides-Savvopoulou et al [@CR10]; Bodamer et al [@CR24]; Powers et al [@CR160]; Guigonis et al [@CR79]), pulmonary thrombosis (Powers et al [@CR160]; Thauvin-Robinet et al [@CR203]; McCully [@CR131]; Baumgartner et al [@CR13], [@CR14]; Van Hove et al [@CR217]), cor pulmonale (Profitlich et al [@CR162], [@CR163]) and cerebrovascular complications (Brunelli et al [@CR31]; Geraghty et al [@CR67]).

tHcy levels above 45 μmol/L have been reported to be associated with the development of vascular complications in several patients (Carrillo-Carrasco et al [@CR39]). Remarkably, the original case of cblC disease presenting diffuse vascular lesions with proliferative fibrous intimal plaques and focal necrosis of the artery wall contributed to the development of the homocysteine theory of arteriosclerosis (McCully [@CR132]).

With appropriate treatment, the incidence of thromboembolic complications can be reduced and may even be prevented in late onset patients (Huemer et al [@CR94]).

**Outcome: survival, severe organ complications** Recommendation 15The incidence of vascular complications is significantly reduced with appropriate treatment in late onset patients and may be prevented in early onset patients with remethylation disorders. (Quality of the evidence: moderate)

Neurocognitive and psychiatric problems {#Sec22}
---------------------------------------

Neurodevelopmental impairment of varying degrees is common in combined remethylation defects. Patients with early-onset cblC disease present with a wide range of neurological manifestations that include microcephaly, hydrocephalus, hypotonia, cognitive defects and seizures. Cognitive defects can be variable, are related to disease severity and treatment onset but may also continue to worsen despite treatment. Two treated patients with early-onset cblC disease were longitudinally followed using neuropsychological testing. These tests showed a decline in attention and executive functions, while other skills were relatively spared (Beauchamp et al [@CR15]). Developmental delay with impairment of verbal and non-verbal cognitive skills was also documented at follow-up of cblF patients despite treatment (Alfadhel et al [@CR3]; Gailus et al [@CR66]), but in some early treated patients, neurocognitive outcome was satisfactory (Miousse et al [@CR139]; Armour et al [@CR7]). Information on outcome in the cblJ defect (Coelho et al [@CR44]) is extremely limited; two reported patients responded well to methylcobalamin (Kim et al [@CR104]). In the cblD-MMA/HC defect, some survivors showed improvement or even normalisation of neurocognitive function (Suormala et al [@CR199]; Miousse et al [@CR138]).

Patients with late-onset disease can show progressive encephalopathy with regression, deterioration in school or work performance, behavioural and personality changes possibly resulting in dementia, psychosis, episodes of acute mental confusion, lethargy and seizures that improve under specific treatment (Huemer et al [@CR94]).

Epilepsy is a common but nonspecific occurrence in patients with remethylation disorders. The EEG and seizure patterns are nonspecific. Severely affected patients may be difficult to treat and may have recurrent status epilepticus (Biancheri et al [@CR20]).

Brain MRI abnormalities are common in remethylation defects and include diffuse cerebral atrophy, white matter changes, basal ganglia lesions and hydrocephalus.

The most common imaging findings in the early-onset cblC cases are variable degrees of white matter abnormality with T2 hyperintensity in periatrial and periventricular white matter, with thinning of the corpus callosum. Basal ganglia lesions and hydrocephalus have also been described, and may be attributable to microvascular abnormalities (Greitz [@CR77]). In one cohort of young early-onset cblC patients, there was a high incidence of craniocaudal shortening of the pons on sagittal MR images (Weisfeld-Adams et al [@CR227]).

Cerebral atrophy and deep white matter bulk loss, which is more pronounced posteriorly, were significant findings in late-onset cblC disease patients (Ogier de Baulny et al [@CR153]; Longo et al [@CR122]; Rossi et al [@CR174]; Wang et al [@CR223]). Bilateral abnormalities of the cerebellar cortex were found in one patient (Wang et al [@CR223]).

The pathophysiological mechanisms underlying the white matter abnormalities detected by MR imaging have been associated with oedema and abnormal myelination. Myelination is closely related to methylation capacity whereby deficiency of SAM in the CSF was shown to be associated with impaired myelinisation (Rossi et al [@CR174]). Moreover, a decrease in N-acetyl aspartate (NAA) and increased lactate in the basal ganglia or in the periventricular white matter has been observed on brain MR spectroscopy (Longo et al [@CR122]; Wang et al [@CR223]).

Spongiform white matter degeneration and demyelination of the dorsal and lateral columns of the cord or subacute combined degeneration of the spinal cord (SACD) are known complications in remethylation disorders (Huemer et al [@CR94]; Liu et al [@CR121]). Changes are similar to classical adult spinal cord degeneration due to, e.g. severe nutritional vitamin B12 deficiency (Scalabrino et al [@CR179]; Maamar et al [@CR124]). Subacute combined degeneration of the spinal cord may be the presenting symptom in late onset patients or the consequence of insufficient treatment. Symptoms are progressive and include numbness of lower extremities, gait disturbances, incontinence, progressive leg weakness with spastic paraparesis and tetraplegia (Mitchell et al [@CR140]; Ben-Omran et al [@CR17]; Thauvin-Robinet et al [@CR203]; Augoustides-Savvopoulou et al [@CR10]; Powers et al [@CR160]; Roze et al [@CR175]; Tsai et al [@CR211]; Bodamer et al [@CR24]; Shinnar and Singer [@CR188]).

Behavioural problems are frequent in patients with early-onset remethylation disorders. Psychiatric manifestations may be the presenting sign in patients with late-onset remethylation disorders. Dementia, behavioural problems and psychiatric symptoms have frequently been observed in the combined (Roze et al [@CR175]; Liu et al [@CR121]; Huemer et al [@CR94]) as well in isolated remethylation disorders (Huemer et al [@CR95]) and MTHFR deficiency (Birnbaum et al [@CR22]). In early onset cases, behavioural problems and psychiatric symptoms can evolve over time despite treatment (Fischer et al [@CR58]). Late-onset cases may present with rather non-specific psychiatric and behavioural symptoms, which respond well to timely treatment (Ben-Omran et al [@CR17]).

Ophthalmological problems {#Sec23}
-------------------------

Visual dysfunction is very frequent in patients with early onset remethylation disorders and can be rapidly progressive while late-onset patients rarely exhibit eye disease. Current treatment does not seem to modify the progression of visual disease significantly.

Maculopathy, progressive retinal dysfunction, visual impairment, nystagmus, strabismus (Ricci et al [@CR168]; Schimel and Mets [@CR182]; Gerth et al [@CR68]; Weisfeld-Adams et al [@CR228]) and less frequently optic atrophy (Patton et al [@CR157]; Weisfeld-Adams et al [@CR228]) are seen in most patients with early onset cblC disease. Although rod cell sensitivity was reported to improve in a patient with cblC disease following normalisation of plasma Met levels (Tsina et al [@CR213]) generally retinal dysfunction can be progressive and even lead to blindness despite treatment and stabilised systemic function (Fischer et al [@CR58]).

The first signs of eye disease are frequently noted several weeks after birth and include "wandering eye movements," inability to fixate and nystagmus. The fundoscopic exam can reveal the salt-and-pepper pigmentary macular changes that progresses to the characteristic "bull's eye" maculopathy characterised by a hypopigmented perimacular zone surrounded by a hyperpigmented ring or coloboma like lesions (Robb et al [@CR169]; Grant et al [@CR76]; Weisfeld-Adams et al [@CR228]). Retinopathy can be revealed by the electroretinogram well before clinical signs are apparent (Ogier de Baulny et al [@CR153]; Weisfeld-Adams et al [@CR228]) showing a progressive decline in scotopic (cones) and/or photopic (rods) responses (Schimel and Mets [@CR182]; Robb et al [@CR169]; Gerth et al [@CR68]; Gaillard et al [@CR65]; Weisfeld-Adams et al [@CR228]).

Ocular coherence tomography, electroretinogram and visual evoked potentials, are extremely useful diagnostic and monitoring tools (Weisfeld-Adams et al [@CR228]). Knowledge and awareness of visual dysfunction, particularly in children with early-onset disease, allows initiation of appropriate early vision intervention programs and support (Gerth et al [@CR68]).

Late onset patients rarely have severe visual disease (Fuchs et al [@CR64]; Fischer et al [@CR58]; Gerth et al [@CR68]). Minimal pigmentary retinal abnormalities have been observed in some cases (Gerth et al [@CR68]; Weisfeld-Adams et al [@CR228]) and the classical "bull's eye" picture has only been described in one late-onset patient (Collison et al [@CR46]).

**Outcome: visual and neurocognitive function** Recommendation 16As knowledge and awareness of visual dysfunction progression allows timely initiation of appropriate vision intervention programs and support, we recommend that every patient newly diagnosed with a remethylation disorder should receive an ophthalmological consultation independent of the age at diagnosis and severity of disease. (Quality of the evidence: low)

Disease course and outcome in isolated remethylation disorders (cblD-HC, cblE, cblG) {#Sec24}
====================================================================================

Disease course and outcome in isolated remethylation disorders generally share many features with the combined disorders.

Mortality {#Sec25}
---------

Deceased patients have been reported in the literature but the database is too small to make a more general statement on mortality.

Renal disease, microangiopathy and anaemia {#Sec26}
------------------------------------------

Atypical HUS and glomerulopathy have been reported in single patients (Paul et al [@CR158]; Huemer et al [@CR95]). Macrocytic anaemia in isolated remethylation defects often responds to treatment (Harding et al [@CR88]; Vilaseca et al [@CR218]).

Vascular problems {#Sec27}
-----------------

Thromboembolism may lead to severe clinical pathology but has only rarely been reported (Huemer et al [@CR95]).

Neurocognitive and psychiatric problems {#Sec28}
---------------------------------------

Muscular hypotonia, seizures, cognitive impairment, behavioural problems, psychiatric symptoms, feeding problems (Watkins and Rosenblatt [@CR225]; Huemer et al [@CR95]) as well as microcephaly, brain atrophy and white matter changes (Zavadáková et al [@CR235]) are characteristic findings during the disease course (Watkins and Rosenblatt [@CR225]). Hydrocephalus has rarely been reported (Huemer et al [@CR95]).

Ophthalmological problems {#Sec29}
-------------------------

Eye disease, mainly comprising retinopathy, nystagmus and strabismus is frequently observed and seems not to respond well to treatment (Watkins and Rosenblatt [@CR225]; Huemer et al [@CR95]).

Disease course and outcome in MTHFR deficiency {#Sec30}
==============================================

Mortality {#Sec31}
---------

Recent experience suggests that betaine treatment if initiated early reduces mortality in patients with MTHFR deficiency (Diekman et al [@CR52])

Vascular problems {#Sec32}
-----------------

Arterial and venous thrombosis are generally rare and predominantly encountered in adolescent or adult patients (Visy et al [@CR219]; Tonetti et al [@CR205]).

Neurocognitive problems {#Sec33}
-----------------------

Severe neurological signs with some age-related variations characterise MTHFR deficiency. Neurological symptoms in MTHFR range from seizures, lethargy, apnoea and coma in early infancy to gait disturbances with lower limb spasticity, weakness, psychiatric behaviour such as schizophrenia-like psychosis (Mudd and Freeman [@CR148]; Regland et al [@CR166]; Pasquier et al [@CR155]), and visual problems in adolescence/adulthood (Haworth et al [@CR90]; Birnbaum et al [@CR22]). Neonates and young infants exhibit acute neurological deterioration, which may be fatal or leave severe neurological deficits. Older individuals typically exhibit progressive triphasic deterioration: an initial period of normal development, then a second phase with acquired microcephaly and psychomotor delay, followed by abrupt deterioration associated with respiratory failure that may be fatal.

In early onset severe forms clinical sequelae associated with MTHFR deficiency include microcephaly, hydrocephalus, seizures, hypotonia and global development delay, whereas in the adolescence onset form mental retardation and progressive encephalopathy are present (Arn et al [@CR8]; Bishop et al [@CR23]; Schiff et al [@CR181]).

Some patients develop leukoencephalopathy and lower limb-dominant demyelinating polyneuropathy (Walk et al [@CR221]) and may have subacute degeneration of the spinal cord (Hyland et al [@CR98]). The peripheral neuropathy has been related to the low level of serum folic acid (Nishimura et al [@CR151]). Seizures are variable in type and include myoclonic, clonic and/or tonic episodes. Infantile spasms have been described (Prasad et al [@CR161]). Cerebral atrophy and white matter changes are common (Arn et al [@CR8]; Birnbaum et al [@CR22]).

Early treated patients exhibit a more favourable outcome (Schiff et al [@CR181]; Diekman et al [@CR52]).

In MTHFR deficiency, early diagnosis and treatment are usually associated with better neurological outcome.

The effects of treatment on clinical outcome {#Sec34}
============================================

Impact of prenatal treatment on outcome {#Sec35}
---------------------------------------

Prenatal maternal treatment with parenteral OHCbl has anecdotally been used. For cblC disease, Trefz et al ([@CR210]) report a favourable outcome of a pregnancy with an affected fetus (sibling to a severely affected child) after treatment of the mother with high-dose OHCbl (30 mg/week) and 5 mg/day folic acid from week 15 of pregnancy. Prenatal treatment with lower OHCbl doses resulted in biochemical improvement. Organ complications such as microangiopathy as present in the patient's sibling were not observed but the patient developed eye disease and neurocognitive impairment (Huemer et al [@CR93]). There is no evidence regarding prenatal treatment for the other diseases.

**Outcome: survival, severe organ damage** Recommendation 17We suggest that prenatal maternal treatment may be considered in a pregnancy with a fetus with proven cblC disease. (Quality of the evidence: low)

Improving the outcome in the acutely ill patient with a suspected or proven remethylation disorder {#Sec36}
--------------------------------------------------------------------------------------------------

Remethylation disorders generally present as chronic, slowly progressive neurological disease but may also present with acute deterioration on the background of chronic disease or with new-onset life-threatening complications. Individuals of all ages may manifest with a sudden thromboembolic event, microangiopathic kidney or pulmonary disease, cardiomyopathy, loss of ambulation or more commonly with acute encephalopathy, displaying epileptic seizures impaired consciousness or acute behavioural deterioration. Restoration of methylation capacity with appropriate medication may reverse many of the acute clinical signs (Fischer et al [@CR58]; Huemer et al [@CR94]) (Fig. [2](#Fig2){ref-type="fig"}).

**Outcome: survival, severe organ damage; neurocognitive impairment** Recommendation 18We strongly recommend immediate treatment with parenteral cobalamin in suspected cases. (Quality of the evidence: moderate)Recommendation 19We recommend consideration of betaine treatment as soon as hyperhomocysteinaemia is proven and normal/low methionine confirmed. (Quality of the evidence: moderate)Recommendation 20We suggest consideration of additional enteral supplementation with folinic acid or L-methionine in individual cases. (Quality of the evidence: low)

Improving the outcome: long-term management of cobalamin-related combined and isolated remethylation disorders {#Sec37}
--------------------------------------------------------------------------------------------------------------

Most of the knowledge about the management of remethylation disorders is derived from the experience with individuals with the cblC defect, the most frequent of the disorders. In clinical practice the rarer combined disorders of the cblD-MMA/HC, cblF and cblJ types as well as the isolated remethylation disorders are generally managed identically but experience concerning treatment efficacy is considerably less and weaker.

Treatment of individuals with the remethylation disorders aims to improve clinical features and metabolic abnormalities by reducing tHcy and normalising Met and---in combined disorders---MMA (Table [7](#Tab7){ref-type="table"}).Table 7Recommended treatment of remethylation disordersDrugs with proven clinical effectTreatments without proven clinical effectTo be avoidedCobalamin related remethylation disordersOHCbl parenteral\
BetaineFolate/folinic acid\
L-Carnitine\
Methionine\*Nitrous oxide\
Protein restrictionMTHFR deficiencyBetaineFolinic acid/ 5-Methylfolate\*\
L-Carnitine\
Methionine\*Nitrous oxide\
Folic acid\
Protein restriction^\*^Has been applied with clinical benefit in single cases

### Cobalamin {#Sec38}

Cobalamin is the cofactor of methionine synthase. In the cblC defect, hydroxocobalamin (OHCbl) appears to be more effective than cyanocobalamin (CNCbl) (Andersson and Shapira [@CR4]; Bodamer et al [@CR24]). Froese et al ([@CR62]) describe that, e.g. MMAMHC with the c.482G\>A (R161Q) mutation binds OHCbl with more affinity than CNCbL. The parental route of administration (IV, SQ or IM) has been proved to be beneficial in patients with the cblC defect (Van Hove et al [@CR217]), whereas oral OHCbl alone seems to be ineffective (Brunelli et al [@CR31]; Bartholomew et al [@CR12]; Gold et al [@CR70]; Frattini et al [@CR61]). Long-term IV application is impracticable and the subcutaneous route seems to be less effective than IM injections (Thauvin-Robinet et al [@CR203]). Many centres use 1 mg of parenteral OHCbl daily in neonates (assuming a body weight of 3 kg, the dosage is 0.33 mg/kg/day). In the long-term treatment, as patients stabilise, the frequency of administration is decreased to minimise the frequency of injections. However, determination of optimal doses and intervals between injections is hampered by very great variation in patient features (Dionisi-Vici et al [@CR53]; Ogier de Baulny et al [@CR153]). Some recent reports suggest that higher OHCbl doses (plasma levels near 1,000,000 pg/ml) can provide a better metabolic control and dose escalation seems to be effective in several reports, including a case of pregnancy in a cblC affected female (Brunel-Guitton et al [@CR30]). In 2002 Van Hove et al ([@CR217]) described a good response to OHCbl dose escalation regarding metabolic and clinical condition in two cblC patients presenting with thrombotic microangiopathies (TMAs). During 13 years of follow up in a cblC patient Carrillo-Carrasco et al ([@CR39]) observed a considerable dose-dependent reduction of MMA and tHcy plasma levels and an elevation of methionine levels as the dose of IM OHCbl was increased. Matos et al [@CR130] performed an open-label study in five cblC patients to determine the effect of OHCbl dose escalation on the clinical and biochemical condition. They observed a good metabolic response in 2/5 patients, whereas clinical response was quite variable and not clearly related to metabolic improvement. In early onset cblC disease, tHcy mostly cannot be normalised; levels between 40 and 60 μmol/L are typically reached. In some late onset patients, tHcy has been normalised.

There is limited experience with OHCbl (1000 μg/day) treatment in cblD-MMA/HC disease but there seems to be a response to treatment (Miousse et al [@CR138]; Suormala et al [@CR199]). Most patients with cblE and cblG disease were treated with OH-Cbl and seemed to benefit (Huemer et al [@CR95], [@CR96]). As OH-Cbl is generally used to treat other cobalamin-related remethylation disorders than cblC disease, no sufficient data is available on the clinical efficacy of other cobalamin preparations .

In conclusion, OHCbl treatment is usually started at a dosage of 1 mg IM daily and then it should be titrated individually based on metabolic response.

**Outcome: survival and severe organ damage** Recommendation 21We strongly recommend using parenteral OHCbl in treating patients with the cblC defect and other cobalamin-related remethylation disorders. (Quality of the evidence: high)Recommendation 22We recommend applying a starting dose of 1000 μg (1 mg) OHCbl daily given parenterally in patients with the cblC defect. This regime has also been applied in other cobalamin-related remethylation defects. (Quality of the evidence: low)Recommendation 23We suggest that the minimum effective OHCbl dose and frequency of administration should be individually titrated. Escalating doses of OHCbl may result in biochemical improvement; however, significant clinical benefit remains to be proven. Frequency of administration of OHCbl ranges between daily and weekly without evidence of advantage of one over the other. (Quality of the evidence: low)

### Betaine {#Sec39}

Betaine derives from choline and is a potent methyl group donor involved in the process of remethylation of Hcy to Met via betaine-homocysteine methyltransferase in the liver, thus bypassing the MeCbl-dependent pathway. Betaine needs to be supplemented orally and decreases Hcy levels. The knowledge about betaine pharmacokinetics is limited (Schwahn et al [@CR184]). It has been suggested that frequent administration of a moderate dose may provide clinical and biochemical benefit (Ucar et al [@CR214]). Betaine or OHCbl alone may not result in sufficient metabolic control, but they seem to have synergistic effects (Bartholomew et al [@CR12]). Betaine is usually administered at a dose of up to 250 mg/kg/day in children (Beauchamp et al [@CR15]; Schiff et al [@CR181]), but has been used at a dose of 850 mg/kg/day to treat cor pulmonale in a patient with the cblC defect (Profitlich et al [@CR162], [@CR163]). Betaine has also been used during pregnancy with no neonatal adverse effect (Pierre et al [@CR159]). Anhydrous betaine is the preferred formulation.

**Outcome: survival and severe organ damage** Recommendation 24We recommend oral betaine treatment in cblC disease and other cobalamin-related remethylation disorders (Quality of the evidence: low)Recommendation 25We suggest that the minimum effective betaine dose should be individually titrated to improve the levels of tHcy and methionine. (Quality of the evidence: low)

### Side effects of treatment with cobalamin and betaine {#Sec40}

Few side effects related to cblC disease treatment have been reported. These are usually scarce and reversible as soon as the treatment is withdrawn.

OHCbl side effects such as red discoloration of the urine and skin, hypersensitivity and photosensitivity reactions, nausea, infusion site reactions and headache have rarely been reported in patients receiving high doses. Mostly, parenteral OHCbl even in doses as high as 20 mg per day have been tolerated without side effects (Carrillo-Carrasco et al [@CR39]).

In a single case, teeth discoloration occurred after 1 month of OHCbl (1 mg/day IM) and folinic acid (10 mg/day) treatment and improved after folinic acid discontinuation (Augoustides-Savvopoulou et al [@CR10]).

Long-tem follow up case series and case reports indicate that betaine is generally well tolerated and safe even at high doses (3--6 g/day in infants; 9 g/day in adults) (Ogier De Baulny et al [@CR153]; Thauvin-Robinet et al [@CR203]). However, in a 15-month-old, epileptic crises have been observed soon after initiation of betaine treatment (250 mg/kg/day) (Enns et al [@CR56]).

Betaine decreases Hcy levels at the expense of increasing Met. The clinical relevance of high Met is under discussion but very high levels have been related to cerebral oedema. In a 10-year-old female with classical homocystinuria plasma Met increased to \>3000 μmoL/L under betaine treatment (200 mg/kg/day). The girl developed clinical signs and radiological evidence of cerebral oedema which resolved when betaine was discontinued and Met levels returned to normal (Yaghmai et al [@CR232]). Devlin et al ([@CR51]) reported on a similar clinical course in a boy at a plasma Met level of 1190 μmol/L. Therefore, caution is required and betaine should immediately be withdrawn in any case of any symptoms suggesting increased intracranial pressure or very high Met levels (Lawson-Yuen and Levy [@CR113]).

### Folates {#Sec41}

Folate has been frequently used as adjunctive therapy in patients with cblC disease. Folinic acid (5-formyl-THF) is the most stable form of the reduced vitamin and crosses the blood brain barrier more efficiently than folic acid (Spector [@CR192]). Daily doses from 5 to 30 mg, divided in 2--3 administrations/week of folate or folinic acid (Carrillo-Carrasco et al [@CR47]; Schiff et al [@CR181]) have been used. In the majority of reported patients, folic acid rather than folinic acid has been used in the long-term treatment. In some cases no beneficial effect of the adjunctive therapy with folic or folinic acid has been reported (Enns et al [@CR56]; Bartholomew et al [@CR12]; Fischer et al [@CR58]) but no long-term studies have been performed.Recommendation 26Results failed to demonstrate or exclude a beneficial or detrimental effect of folic and/or folinic acid as adjunctive therapy in patients with cblC disease and other cobalamin-related remethylation disorders. (Quality of the evidence: low)

### Levocarnitine {#Sec42}

Levocarnitine facilitates the excretion of propionyl groups and prevents carnitine deficiency, since the *de novo* synthesis of carnitine depends on methionine and may be decreased in cblC patients. Some reports in literature show no beneficial effect of adding carnitine to the long-term treatment of cblC disease (Enns et al [@CR56]; Bartholomew et al [@CR12]). There is no clear consensus about the recommended dose and this can range between 50 and 200 mg/kg/day.Recommendation 27Results failed to demonstrate or exclude a beneficial or detrimental effect of oral carnitine as adjunctive therapy in patients with cblC disease and other cobalamin-related remethylation disorders. (Quality of the evidence: low)

### Dietary restrictions {#Sec43}

Few reports describe the use of dietary restriction in cblC patients, mainly with no beneficial effect on metabolic control (Carrillo-Carrasco et al [@CR39]; Enns et al [@CR56]). Huemer et al ([@CR93]) report significantly lower MMA excretion upon protein restriction (methionine-free, threonine-free, valine-free, isoleucine-low formula). However, there is evidence suggesting a possible role of low methionine as a contributing factor for the pathogenesis of cblC disease (Martinelli et al [@CR129]) and other remethylation disorders. Met is essential in patients with remethylation defects and its plasma levels should be maintained in the normal range. Patients on protein-restricted diets had lower height-for-age z-score. Patients consuming medical foods with presumably low Met supply had lower head circumference and lower plasma Met concentrations (Manoli et al [@CR127]). For these reasons, methionine-free formulas and protein restriction leading to low methionine plasma levels is contraindicated in cblC patients (Ogier de Baulny et al [@CR153]; Manoli et al [@CR127]).

**Outcome: survival, severe organ damage; neurocognitive impairment** Recommendation 28We strongly recommend not to restrict protein in cblC disease and other remethylation disorders. (Quality of the evidence: moderate)

### Amino acid supplementation {#Sec44}

In patients with cblC defects methionine and cysteine supplements are mostly not required to maintain normal plasma levels of these two amino acids and in a recent retrospective multicentre study evaluating clinical, biochemical and therapeutic measures in 88 cblC patients (Fischer et al [@CR58]) supplemental Met was used only in one patient; cysteine supplementation was never applied. Some patients were treated with betaine and Met in combination when plasma Met was low (Smith et al [@CR191]).

**Outcome: survival, severe organ damage; neurocognitive impairment** Recommendation 29Met is essential in patients with remethylation defects and we recommend maintaining its plasma levels in the normal range; if necessary this may be achieved by oral methionine supplementation. (Quality of the evidence: low)

**Improving the outcome: long-term management of MTHFR deficiency**

### Betaine {#Sec45}

In MTHFR deficiency betaine in a variable dose of 100--250 mg/kg/day in children and 5--20 g/day in adults is used to increase systemic Met levels. A meta-analysis of case reports (Diekman et al [@CR52]) revealed that betaine treatment at a dosage of 100 mg/kg/day or more was clearly associated with increased survival. Only two of 26 patients died after initiation of treatment. Furthermore, early treatment was associated with normal psychomotor development in all five patients. In contrast, none of the 19 patients in the delayed-treatment group (untreated patients excluded) had normal psychomotor development. Nevertheless, psychomotor development stabilised or improved in all 17 surviving patients in whom betaine treatment was initiated late. Anhydrous betaine is the preferred formulation.

**Outcome: survival, severe organ damage; neurocognitive impairment** Recommendation 30We strongly recommend early treatment with betaine as it improves clinical outcome and prevents neurological deterioration in MTHFR deficiency. (Quality of the evidence: high)

*See also recommendation 13*

### Folates {#Sec46}

In MTHFR deficiency 5-methylTHF synthesis is impaired, resulting in low levels of methyl-tetrahydrofolate (CH3-THF) in the central nervous system. There have been some reports describing the use of folic acid (5--80 mg/day) with good (Al Tawari et al [@CR2]; Munoz et al [@CR150]) or poor (Holme and Ronge [@CR91]; Ucar et al [@CR214]) response. A dose--response relationship was not observed (Holme and Ronge [@CR91]). A combination of folic and folinic acid was associated with favourable outcome (Tallur et al [@CR201]; Lossos et al [@CR123]). It has recently been shown that folic acid may exacerbate cerebral CH3-THF deficiency (Hyland et al [@CR99]) and it has therefore been suggested to avoid folic acid and preferably use folinic acid or 5-CH3-THF. However, therapeutic 5-CH3-THF in a daily dose as high as 45 mg failed to correct the low CSF levels in a patient with MTHFR deficiency (Knowles et al [@CR107]; Schiff and Blom [@CR180]). There is at present no consensus concerning the most effective dosage of folinic acid or 5-CH3-THF and the problem of the assumed instability of 5-CH3-THF has not yet been solved.

**Outcome: neurocognitive impairment** Recommendation 31Results failed to demonstrate or exclude a beneficial or detrimental effect of folic or folinic acid or 5-CH3THF as adjunctive therapy to restore cellular and cerebral folate deficiency in MTHFR deficiency on clinical outcome. (Quality of the evidence: low).

### Other substances {#Sec47}

The data basis addressing the efficacy of vitamin B6, cobalamin, riboflavin and carnitine is not reliable; various dosages and combinations of these substances have been used and their clinical efficacy cannot be assessed (Huemer et al [@CR97]).

### Methionine supplementation {#Sec48}

In a very small number of patients, the clinical condition improved with supplementation of methionine (Schiff et al [@CR181]; Tortorelli et al [@CR207]), however, the data basis is not reliable enough to allow delineation of a recommendation.

Improving clinical outcome: management of general anaesthesia in remethylation disorders {#Sec49}
----------------------------------------------------------------------------------------

A fatal adverse event was reported in a patient with MTHFR deficiency anaesthetised with nitrous oxide (N2O) which is a known inhibitor of methionine synthase (Selzer et al [@CR185]; Erbe and Salis [@CR57]). In seven patients with the cblC and one with the cblG defect, propofol was safe and effective as an induction and maintenance agent for elective short procedures in metabolically and hemodynamically stable patients (Ktena et al [@CR109]).Recommendation 32We strongly recommend against the use of nitrous oxide in patients with remethylation disorders. (Quality of the evidence: high)

Improving clinical outcome: management of pregnancy in remethylation disorders {#Sec50}
------------------------------------------------------------------------------

There are only three reported cases of pregnancies in women with the cblC defect and thus no recommendations can be delineated. An asymptomatic woman was identified when low carnitine levels were found in her healthy child's newborn screening sample (Lin et al [@CR120]). Brunel-Guitton et al ([@CR30]) describe successful outcome of a pregnancy in a treated woman with the cblC defect. Acetylsalicylic acid at the antiplatelet oral dose of 80 mg/day was applied during pregnancy and delivery and specific treatment with OHCbl, folic acid and carnitine was started at 15 weeks of gestation. The OHCbl and carnitine administration was adjusted to maintain a decrease of tHcy and an increase of total carnitine plasma levels. Recently a woman with late-onset cblC, also treated from the 15th week of gestation and giving birth to a healthy child has been reported (Liu et al [@CR121]). So far, pregnancies in women with other remethylation defects have not been reported.

Closing remarks {#Sec51}
===============

These guidelines are the result of the evaluation of available information from the literature based on the GRADE methodology and are aimed at delivering recommendations based on the best available data. The rarity of cobalamin-related remethylation disorders and MTHFR deficiency, the absence of larger data samples from international registries until recently and data mainly derived from case reports, case series or expert opinion results in a low quality of the evidence for several of the recommendations made. The working group responsible for this guideline commits itself to revise this work in the future.
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